Design and Development of an Antigen Test for SARS-CoV-2 Nucleocapsid Protein to Validate the Viral Quality Assurance Panels
Viruses · 2024
DOI: 10.3390/v16050662 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Partha Ray und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, CA 92093, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Coronavirus Nucleocapsid Proteins, COVID-19, Antigens, Viral. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NLM NIH HHS, The NIH RADx-Radical Data Coordination Center (DCC).
Abstract (Originalsprache)
The continuing mutability of the SARS-CoV-2 virus can result in failures of diagnostic assays. To address this, we describe a generalizable bioinformatics-to-biology pipeline developed for the calibration and quality assurance of inactivated SARS-CoV-2 variant panels provided to Radical Acceleration of Diagnostics programs (RADx)-radical program awardees. A heuristic genetic analysis based on variant-defining mutations demonstrated the lowest genetic variance in the Nucleocapsid protein (Np)-C-terminal domain (CTD) across all SARS-CoV-2 variants. We then employed the Shannon entropy method on (Np) sequences collected from the major variants, verifying the CTD with lower entropy (less prone to mutations) than other Np regions. Polyclonal and monoclonal antibodies were raised against this target CTD antigen and used to develop an Enzyme-linked immunoassay (ELISA) test for SARS-CoV-2. Blinded Viral Quality Assurance (VQA) panels comprised of UV-inactivated SARS-CoV-2 variants (XBB.1.5, BF.7, BA.1, B.1.617.2, and WA1) and distractor respiratory viruses (CoV 229E, CoV OC43, RSV A2, RSV B, IAV H1N1, and IBV) were assembled by the RADx-rad Diagnostics core and tested using the ELISA described here. The assay tested positive for all variants with high sensitivity (limit of detection: 1.72–8.78 ng/mL) and negative for the distractor virus panel. Epitope mapping for the monoclonal antibodies identified a 20 amino acid antigenic peptide on the Np-CTD that an in-silico program also predicted for the highest antigenicity. This work provides a template for a bioinformatics pipeline to select genetic regions with a low propensity for mutation (low Shannon entropy) to develop robust ‘pan-variant’ antigen-based assays for viruses prone to high mutational rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, CA 92093, USA.
- Department of Pathology, University of California, San Diego, CA 92093, USA.
ORCID-Profile: Partha Ray, Howard Brickner, Aaron Garretson, Westley Van Zant, Aaron F Carlin, Eliah S Aronoff-Spencer
Förderung
- NLM NIH HHS
- The NIH RADx-Radical Data Coordination Center (DCC)
Zitieren
APA
Ray, P., Ledgerwood-Lee, M., Brickner, H., Clark, A. E., Garretson, A., Graham, R., Van Zant, W., Carlin, A. F., & Aronoff-Spencer, E. S. (2024). Design and Development of an Antigen Test for SARS-CoV-2 Nucleocapsid Protein to Validate the Viral Quality Assurance Panels. Viruses. https://doi.org/10.3390/v16050662
Vancouver
Ray P, Ledgerwood-Lee M, Brickner H, Clark AE, Garretson A, Graham R, et al. Design and Development of an Antigen Test for SARS-CoV-2 Nucleocapsid Protein to Validate the Viral Quality Assurance Panels. Viruses. 2024. doi:10.3390/v16050662
BibTeX
@article{Ray2024,
author = {Ray, Partha and Ledgerwood-Lee, Melissa and Brickner, Howard and Clark, Alex E and Garretson, Aaron and Graham, Rishi and Van Zant, Westley and Carlin, Aaron F and Aronoff-Spencer, Eliah S},
title = {Design and Development of an Antigen Test for SARS-CoV-2 Nucleocapsid Protein to Validate the Viral Quality Assurance Panels},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16050662}
}
EUVIMED